40 81

Cited 0 times in

Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer

Authors
 Hyeok Jun Yun  ;  Minki Kim  ;  Sang Yong Kim  ;  Sungsoon Fang  ;  Yonjung Kim  ;  Hang-Seok Chang  ;  Ho-Jin Chang  ;  Ki Cheong Park 
Citation
 INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, Vol.23(2) : 699, 2022-01 
Journal Title
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Issue Date
2022-01
MeSH
Adult ; Aged ; Animals ; Antineoplastic Agents / therapeutic use* ; Drug Resistance, Neoplasm* ; Female ; Gene Expression Regulation, Neoplastic* ; Humans ; Male ; Mice ; Middle Aged ; Paclitaxel / therapeutic use ; Phenylurea Compounds / therapeutic use ; Prognosis ; Quinolines / therapeutic use ; RNA-Seq ; Sorafenib / therapeutic use ; Thyroid Cancer, Papillary / drug therapy* ; Thyroid Cancer, Papillary / genetics ; Thyroid Cancer, Papillary / physiopathology ; Xenograft Model Antitumor Assays
Keywords
EMT ; FGFR ; drug-resistant papillary thyroid cancer ; lenvatinib ; paclitaxel ; patient-derived papillary thyroid cancer ; sorafenib
Abstract
Thyroid cancer (TC) includes tumors of follicular cells; it ranges from well differentiated TC (WDTC) with generally favorable prognosis to clinically aggressive poorly differentiated TC (PDTC) and undifferentiated TC (UTC). Papillary thyroid cancer (PTC) is a WDTC and the most common type of thyroid cancer that comprises almost 70-80% of all TC. PTC can present as a solid, cystic, or uneven mass that originates from normal thyroid tissue. Prognosis of PTC is excellent, with an overall 10-year survival rate >90%. However, more than 30% of patients with PTC advance to recurrence or metastasis despite anti-cancer therapy; consequently, systemic therapy is limited, which necessitates expansion of improved clinical approaches. We strived to elucidate genetic distinctions due to patient-derived anti-cancer drug-sensitive or -resistant PTC, which can support in progress novel therapies. Patients with histologically proven PTC were evaluated. PTC cells were gained from drug-sensitive and -resistant patients and were compared using mRNA-Seq. We aimed to assess the in vitro and in vivo synergistic anti-cancer effects of a novel combination therapy in patient-derived refractory PTC. This combination therapy acts synergistically to promote tumor suppression compared with either agent alone. Therefore, genetically altered combination therapy might be a novel therapeutic approach for refractory PTC.
Files in This Item:
T202200571.pdf Download
DOI
10.3390/ijms23020699
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Park, Ki Cheong(박기청) ORCID logo https://orcid.org/0000-0002-3435-3985
Yun, Hyeok Jun(윤혁준) ORCID logo https://orcid.org/0000-0001-6004-0782
Chang, Hang Seok(장항석) ORCID logo https://orcid.org/0000-0002-5162-103X
Chang, Ho Jin(장호진) ORCID logo https://orcid.org/0000-0002-8940-3484
Fang, Sungsoon(황성순) ORCID logo https://orcid.org/0000-0003-0201-5567
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/188061
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links